<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394314</url>
  </required_header>
  <id_info>
    <org_study_id>D5670C00001</org_study_id>
    <nct_id>NCT02394314</nct_id>
  </id_info>
  <brief_title>A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, single dose study with 8 cohorts of ascending doses designed to evaluate the&#xD;
      safety and pharmacokinetics of MEDI0382 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-time-in-humans (FTIH), randomized, double-blind study designed to evaluate&#xD;
      the safety, tolerability, and PK of MEDI0382 administered as single-ascending SC doses to&#xD;
      healthy subjects (age 18-45). Eight subjects per cohort will be enrolled in a total of 8&#xD;
      cohorts. The decision whether or not to dose escalate will be based upon data review by the&#xD;
      Dose Escalation Committee (DEC). Within each cohort, the subjects will be randomized to&#xD;
      MEDI0382 or placebo (3:1). Following screening, the study duration for each subject will be&#xD;
      approximately 29 days, consisting of an inpatient evaluation period, and an outpatient&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382</measure>
    <time_frame>28 days post dosing</time_frame>
    <description>Treatment emergent adverse events (TEAEs) and serious adverse events (STEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382</measure>
    <time_frame>28 days post dosing</time_frame>
    <description>GI symptomatology (a composite of nausea and vomiting)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382</measure>
    <time_frame>28 days post dosing</time_frame>
    <description>Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382</measure>
    <time_frame>28 days post dosing</time_frame>
    <description>12 lead electrocardiogram including RR, PR, QRS, QT and QTc intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382</measure>
    <time_frame>28 days post dosing</time_frame>
    <description>Clinical laboratory assessments (serum chemistry, hematology, urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI0382, maximum plasma concentration (Cmax)</measure>
    <time_frame>72 hours postdose</time_frame>
    <description>This variable will be estimated for MEDI0382 where the data allow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI0382, area under the curve concentration (AUC)</measure>
    <time_frame>72 hours post dose</time_frame>
    <description>This variable will be estimated for MEDI0382 where the data allow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ADA to MEDI0382</measure>
    <time_frame>28 days post dose</time_frame>
    <description>This variable will be estimated for MEDI0382 where the data allow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI0382</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0382 administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0382</intervention_name>
    <description>MEDI0382 administered subcutaneously</description>
    <arm_group_label>MEDI0382</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers, ages 18-45&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  BMI &gt;22 and &lt;30 kg/m2 and body weight &gt;70kg&#xD;
&#xD;
          -  Venous access suitable for multiple cannulations&#xD;
&#xD;
          -  Vital signs within normal specified ranges&#xD;
&#xD;
          -  Females must be non-lactating and non-childbearing potential&#xD;
&#xD;
          -  Males must practice 2 effective contraceptive measures if sexually active&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concurrent condition that in the opinion of the investigator would interfere with&#xD;
             the evaluation of the investigational product&#xD;
&#xD;
          -  History or presence of gastrointestinal, renal, or hepatic disease or any other&#xD;
             condition known to interfere with absorption, distribution, metabolism, or excretion&#xD;
             of drugs&#xD;
&#xD;
          -  History of cancer, with the exception of non-melanoma skin cancer&#xD;
&#xD;
          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks&#xD;
             prior to dosing&#xD;
&#xD;
          -  Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at&#xD;
             screening.&#xD;
&#xD;
          -  Concurrent or previous use of a GLP-1 receptor agonist&#xD;
&#xD;
          -  Current or previous use of systemic corticosteroids within the past 28 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Use of any medicinal products or herbal preparations licensed for control of body&#xD;
             weight or appetite is prohibited.&#xD;
&#xD;
          -  Known or suspected history of alcohol or drug abuse within the past 3 years.&#xD;
&#xD;
          -  Positive drug screen&#xD;
&#xD;
          -  Current smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI0382, diabetes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

